Influenza Vaccine Clinical Trial
— PCIRNRT09Official title:
Controlled Comparison in Canadian Seniors of Seasonal Influenza Vaccines for 2011-2012
Verified date | April 2015 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
Based on information from several years of looking at Influenza vaccination doctors know
that:
- Older adults suffer the worst illness and most deaths caused by Influenza illness of
all age groups.
- Older adults do not seem to get as good a level of protection as younger adults after
getting the usual seasonal Influenza vaccine.
Because of this information doctors wonder if one of the new seasonal Influenza vaccines is
more effective or more acceptable.
This study has been designed to answer some of these questions. On this study doctors will
compare 2 new vaccines against the usual seasonal influenza vaccine for protectiveness using
several different testing methods (including the usual tests) and for acceptability.
Status | Completed |
Enrollment | 953 |
Est. completion date | May 2012 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Written informed consent provided by the subject, who can be male or female - Subjects who the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, record safety observations and able to converse with study personnel including by personal telephone) - Age 65 years or older at Visit 1 - Generally good health (stable chronic conditions acceptable), living independently or with minimal assistance (Clinical Frailty score 1-5) (33) and able to attend clinic appointments - Receipt of at least one dose of TIV within the previous 2 influenza seasons, documented by written record or attested by a confident personal recollection. This refers to the trivalent seasonal vaccine, not the H1N12009 pandemic vaccine. Exclusion Criteria: - receipt of non-study influenza vaccine for 2011-12 - receipt of any live vaccine within 4 weeks or inactivated vaccine within one week of Visit 1 or planned administration of any non-study vaccines between Visits 1 and 2 - systemic hypersensitivity to influenza vaccine, hen's eggs or other vaccine constituent (eg neomycin sulphate, kanamycin, formalin) - severe reaction to any previous influenza vaccine or vaccine component - bleeding disorder, including anticoagulant therapy or thrombocytopenia, that contraindicates IM injection or blood collection (does not include daily low-dose ASA). - incapacity to provide fully informed consent or be attentive to follow-up observations, resulting from cognitive impairment, abuse of alcohol, drug addiction - lack of telephone access, inadequate fluency in English (or French in applicable jurisdictions), uncertain availability during the 3 week study participation period or for the 6 month follow-up visit - immune compromise resulting from disease or immunosuppressive systemic medication use within 3 months of V1 - receipt of blood or blood product within 3 months of V1 - unstable medical condition, as indicated by a requirement for hospitalization or a substantial medication change to stabilize said condition within previous 3 months - Clinical Frailty score of 6-7 (moderately frail or severely frail) - history of Guillain-Barré syndrome |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Canada | Canadian Centre for Vaccinology Dalhousie University | Halifax | Nova Scotia |
Canada | McMaster University | Hamilton | Ontario |
Canada | McGill University Health Center - Vaccine Study Center | Montreal | Quebec |
Canada | The Ottawa Hospital Research Institute, University of Ottawa | Ottawa | Ontario |
Canada | Unité de Recherche en Santé Publique (CHUQ), | Quebec City | Quebec |
Canada | University of Toronto, Mt Sinai Hospital | Toronto | Ontario |
Canada | University of British Columbia, VITALiTY Research Center | Vancouver | British Columbia |
Canada | University of Manitoba, Department of Medicine | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | PHAC/CIHR Influenza Research Network |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HAI response | The primary outcome measures will be the 3-week post-vaccination immune (HAI) responses to the 3 vaccine strains present in each product, assessed by the EMEA/CHMP criteria for evaluation of immune responses to influenza vaccines in persons >60 years of age. | Day 0; Day 21; Day 180 | No |
Secondary | Seroprotection rates using microneutralization titres and cytokine testing | As secondary immunologic outcomes seroprotection rates will be compared between the products using a higher titer (=160) as threshold. Microneutralization titers will be compared among products at the 3 sampling points, using sera from 100 subjects per group. Cross-protection afforded by each vaccine against drift variants of H3N2, H1N1 and B viruses will be assessed using serum panels selected from 50 subjects in each group. Cellular immune responses elicited will be compared in subgroups of 30 subjects per vaccine in the CMI subjset. | Day 0; Day 21; and Day 70 | No |
Secondary | Safety and Acceptability | Safety and acceptability of the vaccines will also be examined and compared as the safety outcomes. The primary outcome measurements will be the rates of local adverse events (pain, redness, swelling, itchiness) as rates of general adverse events are not expected to differ substantially among the products. | Days 0-6; Day 21; Day 70; and Day 180 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03285997 -
A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age
|
Phase 3 | |
Recruiting |
NCT05996549 -
Cost-effectiveness of the Influenza Vaccination
|
Phase 4 | |
Completed |
NCT04546854 -
Influenza 2020/2021
|
N/A | |
Completed |
NCT05157425 -
Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination
|
N/A | |
Completed |
NCT01687517 -
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
|
Phase 3 | |
Completed |
NCT01180699 -
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients
|
N/A | |
Completed |
NCT00760175 -
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients
|
N/A | |
Completed |
NCT00542776 -
Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine
|
N/A | |
Completed |
NCT06304038 -
Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome
|
||
Recruiting |
NCT04086628 -
Influenza Vaccine in Children With Asthma
|
||
Completed |
NCT02960815 -
Imiquimod and Influenza Vaccine for Immunocompromised Patients
|
Phase 2 | |
Completed |
NCT00828555 -
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
|
N/A | |
Completed |
NCT04230343 -
Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour
|
N/A | |
Recruiting |
NCT03399357 -
Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial
|
N/A | |
Completed |
NCT02153671 -
Immunogenicity of H5N1 Vaccine Following H5N2
|
Phase 2 | |
Completed |
NCT00461981 -
A Phase 2 Study to Evaluate Immune Responses of FluMist®
|
Phase 2 | |
Recruiting |
NCT05070494 -
Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT04785794 -
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
|
Phase 1 | |
Completed |
NCT05163847 -
Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults
|
Phase 1 | |
Not yet recruiting |
NCT04355806 -
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
|